Global /Japan /Healthcare /Drug Manufacturers - General /4575

CanBas Co., Ltd.

4575

• TSE: 4575 • Delayed

665JPY -3.8%

4.16 USD

As of 5 June 2026, CanBas Co., Ltd. has a market cap of $82.53M USD, ranking #26925 globally and #2409 in Japan. It ranks #2415 in the Healthcare sector, and #871 in the Drug Manufacturers - General industry.

Global Rank

26925

Country Rank

2409

Sector Rank

2415

Industry Rank

871

Key Stats

Market Cap

$82.53MUSD

13.21B JPY

Enterprise Value

$68.78MUSD

11.01B JPY

Net Income (TTM)

-$7.78MUSD

-1.25B JPY

PB Ratio

5.6

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Takumi Kawabe open_in_new

Employees

Founded

2000

Website

canbas.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.8%	-5.8%	-11%	-23%	-23%	-17%	-35%	-60%	55%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4575 株式会社キャンバス ISIN: JP3244570002 Shares Out.: Shares Outstanding: 19.703M¹ Shares Float: 19.049M² TV: TradingView: TSE: 4575 SA: Stock Analysis: TYO: 4575 YF: Yahoo Finance: 4575.T GF: Google Finance: TYO: 4575 BA: Barron's: 4575 MS: Morningstar: XTKS: 4575	665 JPY	TV: TradingView: TSE: 4575 SA: Stock Analysis: TYO: 4575 YF: Yahoo Finance: 4575.T GF: Google Finance: TYO: 4575 BA: Barron's: 4575 MS: Morningstar: XTKS: 4575

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CanBas Co., Ltd.

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.66B 13.07T JPY 99K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.21B 8.36T JPY 63K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.84B 5.9T JPY 45K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.37B 4.86T JPY 37K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.82B 4.13T JPY 31K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.91B 2.71T JPY 20K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 923K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 663K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 437K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 392K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 350K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 335K%	20.5	Switzerland

chevron_leftBack